Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Kísérleti tanulmány a kis rostos neuropátia előfordulásáról fibromyalgiás betegekben, egészséges alanyokhoz viszonyítva Sudoscan® használatával (NEFI)

2026. november 13. frissítette: University Hospital, Clermont-Ferrand

Fibromyalgia (FM) is characterized by chronic diffuse pain and affects 0.5 to 5% of the population, with a higher prevalence in women1. This condition is characterized by joint and muscle pain, also associated with fatigue, migraine, sleeps disorders, depression and irritable bowel syndrome2. The presentation of these various symptoms varies greatly from one patient to another, with great heterogeneity in clinical, physical, social, psychological and therapeutic responses. . A recent parliamentary inquiry report called for recognition of the disease and recommended to build a unified care path for patients; a collective expertise is led by INSERM to help in patient care. Faced with the heterogeneity of FM, several international studies have attempted to identify subgroups of patients based essentially on clinical symptoms of the disease3-8, including a recent Korean study of 313 patients9, which suggested four groups, but with methodological limitations, not taking into account the new criteria10 for evaluating FM.

Recent studies have also shown that there is a peripheral neuropathic component in the mechanisms of this pathology, demonstrated by a decrease in the density of the epidermal nerve fibers11-12, called small fiber neuropathy (SFN) neuropathy. It is an attack of small sensory and sympathetic nerve fibers, causing pain, paresthesia as well as disturbances of the autonomous system. Other studies also suggested that a significant proportion of patients diagnosed with fibromyalgia had SFN, demonstrated by cutaneous biopsy13-14 or confocal microscopy of the cornea15. A new device, the Sudoscan®, makes it possible to detect a SFN much simpler, faster and less invasive than the technique of ophthalmology or biopsy. Although this Sudoscan® test has been used extensively in conditions such as diabetes16-19, no study has been used to assess the presence of SFN in FM.

The aim of this pilot study is to identify the prevalence of SFN in FM patients, using this new non-invasive device, in order to have a better defined representation of the prevalence of small-fiber neuropathy in an FM population compared to a group of healthy volunteer matched in age, sex, BMI and by menopausal status for women.

A tanulmány áttekintése

Állapot

Befejezve

Körülmények

Beavatkozás / kezelés

Részletes leírás

Only one visit (2 to 3h) :

Inclusion of the patient Clinical examination ; evaluation of pain for FM patients Measurement of the electrochemical conductance of the hands and feet using Sudoscan® Evaluation of quality of life, anxiety, depression, sleep quality, fatigue, catastrophizing and social precarity End of study

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

100

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

      • Clermont-Ferrand, Franciaország, 63003
        • CHU Clermont-Ferrand

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • - Patient over 18 years of age and under 65 years of age,
  • Male or female patient,
  • Patient with fibromyalgia (according to the ACR criteria of 2016),
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance of written consent,
  • Affiliation to the French Social Security system.

Inclusion criteria healthy subjects:

  • Subject of more than 18 years,
  • Woman or man,
  • Healthy voluntary non-painful subjects matched by age (+/- 5 years), by sex, by BMI (+/- 10%) and by menopausal status for women,
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance of written consent,
  • Affiliation to the French Social Security system,
  • Registration or acceptance of registration in the National Register of Volunteers participating in research.

Exclusion Criteria:

  • Exclusion criteria patients:
  • Patient with a physical inability to place the palms of the hands or the soles of the feet on the electrodes of Sudoscan®,
  • Patient with a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test (in particular a disease known to give neuropathies of small fibers: diabetes, Gougerot-Sjögren's disease, vasculitis, sarcoidosis, chronic ethylism ...),
  • Pregnant or nursing woman
  • Patient participating in another clinical trial, or in a period of exclusion, or having received a total amount of compensation in excess of EUR 4500 over the 12 months preceding the start of the trial,
  • Patient benefiting from a measure of legal protection (curatorship, guardianship, safeguard of justice ...),
  • Patient not affiliated to the French Social Security system.

Exclusion criteria healthy subjects :

  • Physical inability to place the palms of the hands or the soles of the feet on the electrodes of Sudoscan®.
  • Medical and / or surgical history judged by the investigator or his representative to be incompatible with the test,
  • Pregnant or nursing woman
  • Participating in another clinical trial, or within the exclusion period, or having received a total amount of compensation in excess of EUR 4500 over the 12 months preceding the start of the trial,
  • Cooperation and an understanding that does not permit strict compliance with the conditions laid down in the Protocol,
  • Benefiting from a measure of legal protection (curatorship, guardianship, safeguard of justice ...),
  • Not affiliated to the French Social Security system.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Diagnosztikai
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: FM patients

50 fibromyalgia patients/50 healthy subjects

Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.

Aktív összehasonlító: Healthy subjects

50 fibromyalgia patients/50 healthy subjects

Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Measure of the electrochemical conductance (µS) using Sudoscan®
Időkeret: at day 1

Evaluation of the prevalence of fibromyalgia patients with small fibro neuropathy in comparison with healthy volunteers by measuring the electrochemical conductance of the palms of the hands (middle right and left hands) and feet (middle right and left) in μS using Sudoscan®.

at day 1

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Biometric criteria
Időkeret: at day 1

Collection of the age in years

at day 1
Biometric criteria
Időkeret: at day 1

Collection of sex, (male or female)

at day 1
Biometric criteria
Időkeret: at day 1

Collection weight in kilograms, height in meters, weight and eight will be combined to report BMI in kg/m²,

at day 1
Biometric criteria
Időkeret: at day 1

phototype Fitzpatrick classification

at day 1
Numerical scale
Időkeret: at day 1

This scale allows the patient to note pain on a graduation with a minimum score of 0 and a maximum score of 10. Higher value represent worse outcome.

at day 1
Brief Pain Inventory
Időkeret: at day 1

The BPI gives two main scores: a pain severity score and a pain interference score

at day 1
Fibromyalgia Impact Questionnaire
Időkeret: at day 1

The revised FIQ questionnaire is a 10-item self-questionnaire that assesses the impact of fibromyalgia. The first item is subdivided into 10 questions that assess the impact of the disease in everyday life

at day 1
Quality of life (SF-12)
Időkeret: at day 1

12 questions and an index is determined for both physical and mental health (0-100). Higher scores indicate greater physical and mental health

at day 1
Anxiety and Depression (HAD)
Időkeret: at day 1

The HAD scale is a 14-item self-administered questionnaire completed by the patient. These items are divided into two subscales: 7 items to assess depression and 7 items to assess anxiety. Higher value represent worse outcome.

at day 1
Depression (Beck Depression Inventory)
Időkeret: at day 1

Each item consists of 4 sentences corresponding to 4 degrees of increasing intensity of a symptom: from 0 to 3. In the counting, it is necessary to take into account the highest rating chosen for the same series. The overall score is obtained by adding the scores of the 13 items. The range of the scale is from 0 to 39. The higher the score, the more the subject is depressed.

at day 1
Pittsburgh Sleep Quality Index
Időkeret: at day 1

19-item self-administered questionnaire used to assess the quality of sleep. Higher value represent worse quality of sleep.

at day 1
Chronic fatigue Severity Scale
Időkeret: at day 1

9-item self-questionnaire to assess the patient's fatigue intensity. The patient is asked to circle a number from 1 to 7 for each question, a low value representing a low intensity. Higher value represents worse fatigue.

at day 1
Pain Catastrophizing Scale
Időkeret: at day 1

This questionnaire consists of 13 items. The patient will have to indicate how much he has thoughts or emotions when he feels pain by giving a score between 0 and 4, 0: not at all, 4: all the time. The final score is the sum of the scores for each question. Higher value represent worse outcome.

at day 1
Assessment of socio-professional category, precariousness and health inequalities (Score EPICES).
Időkeret: at day 1

The EPICES questionnaire consists of 11 binary questions (yes / no) to calculate an individual score indicating the precariousness and inequalities of health ranging from 0 to 100. Higher value represent worse outcome.

at day 1
Measure of the electrochemical conductance (µS) using Sudoscan®
Időkeret: at day 1

Assess the reproducibility (2 passes) of Sudoscan® in each participant: measurement of the electrochemical conductance of the palms of the hands (middle right and left hands) and feet (middle right and left) in μS using the Sudoscan®, 30 minutes after the first measurement.

at day 1

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Gisèle PICKERING, University Hospital, Clermont-Ferrand

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Általános kiadványok

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2017. november 6.

Elsődleges befejezés (Tényleges)

2018. március 14.

A tanulmány befejezése (Tényleges)

2018. március 14.

Tanulmányi regisztráció dátumai

Először benyújtva

2017. november 8.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2017. november 15.

Első közzététel (Tényleges)

2017. november 20.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 17.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 13.

Utolsó ellenőrzés

2017. december 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel